$549 Million is the total value of MPM BioImpact LLC's 33 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 12.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | $118,013,000 | -31.6% | 7,648,268 | 0.0% | 21.52% | -19.6% | |
| ITOS | Sell | iTeos Therapeutics, Inc. | $85,890,000 | +51.0% | 1,844,727 | -12.5% | 15.66% | +77.4% |
| RPTX | Repare Therapeutics, Inc. | $34,584,000 | -19.6% | 1,639,849 | 0.0% | 6.30% | -5.5% | |
| MEIP | New | MEI Pharma, Inc. | $32,977,000 | – | 12,350,971 | +100.0% | 6.01% | – |
| MRUS | Sell | Merus N.V. | $29,488,000 | +42.3% | 927,302 | -1.6% | 5.38% | +67.3% |
| HOWL | Werewolf Therapeutics, Inc. | $28,441,000 | -30.6% | 2,388,011 | 0.0% | 5.18% | -18.4% | |
| HARP | Harpoon Therapeutics, Inc. | $24,135,000 | -4.4% | 3,196,707 | 0.0% | 4.40% | +12.3% | |
| NTLA | Sell | Intellia Therapeutics, Inc. | $18,981,000 | -13.0% | 160,527 | -1.3% | 3.46% | +2.2% |
| TCRR | TCR2 Therapeutics, Inc. | $15,709,000 | -45.2% | 3,370,982 | 0.0% | 2.86% | -35.6% | |
| TPTX | Turning Point Therapeutics, Inc. | $12,943,000 | -28.2% | 271,350 | 0.0% | 2.36% | -15.6% | |
| ONCR | Oncorus, Inc. | $12,527,000 | -43.6% | 2,377,031 | 0.0% | 2.28% | -33.7% | |
| CRNX | Buy | Crinetics Pharmaceuticals Inc. | $10,790,000 | +71.8% | 379,792 | +27.3% | 1.97% | +102.0% |
| CYTK | Sell | Cytokinetics Inc. | $10,587,000 | +19.8% | 232,268 | -6.1% | 1.93% | +40.8% |
| EPIX | Sell | ESSA Pharma, Inc. | $9,495,000 | +73.7% | 668,688 | -2.1% | 1.73% | +104.1% |
| BCRX | Sell | Biocryst Pharmaceuticals Inc. | $9,168,000 | -9.5% | 661,951 | -6.1% | 1.67% | +6.4% |
| TVTX | Sell | Travere Therapeutics Inc. | $8,936,000 | +20.2% | 287,893 | -6.1% | 1.63% | +41.3% |
| GTHX | Sell | G1 Therapeutics, Inc. | $8,748,000 | -24.2% | 856,798 | -0.4% | 1.60% | -10.9% |
| EPZM | Sell | Epizyme, Inc. | $8,563,000 | -57.9% | 3,425,202 | -13.8% | 1.56% | -50.5% |
| YMAB | Sell | YmAbs Therapeutics, Inc. | $7,237,000 | -44.0% | 446,457 | -1.4% | 1.32% | -34.2% |
| GERN | Sell | Geron Corporation | $6,861,000 | -12.6% | 5,623,889 | -1.9% | 1.25% | +2.7% |
| ADCT | Sell | ADC Therapeutics, Inc. | $6,815,000 | -27.2% | 337,396 | -2.1% | 1.24% | -14.4% |
| VSTM | Buy | Verastem, Inc. | $6,707,000 | -22.9% | 3,271,532 | +15.8% | 1.22% | -9.4% |
| HRMY | Sell | Harmony Biosciences Hldgs Inc. | $6,074,000 | +4.5% | 142,437 | -6.1% | 1.11% | +22.7% |
| FOLD | Sell | Amicus Therapeutics Inc. | $5,929,000 | +13.6% | 513,333 | -6.1% | 1.08% | +33.5% |
| NEO | Sell | Neogenomics Inc. | $4,791,000 | -33.6% | 140,422 | -6.1% | 0.87% | -22.0% |
| MIRM | Sell | Mirum Pharmaceuticals Inc. | $4,767,000 | -22.4% | 298,852 | -3.1% | 0.87% | -8.8% |
| AXSM | Sell | Axsome Therapeutics Inc. | $3,907,000 | +7.6% | 103,405 | -6.1% | 0.71% | +26.5% |
| RVMD | Sell | Revolution Medicines, Inc. | $3,676,000 | -10.9% | 146,041 | -2.6% | 0.67% | +4.7% |
| AVDL | Sell | Avadel Pharmaceuticals Plc | $3,033,000 | -22.6% | 375,326 | -6.2% | 0.55% | -9.0% |
| ACAD | New | Acadia Pharmaceuticals Inc | $2,918,000 | – | 125,000 | +100.0% | 0.53% | – |
| AVRO | Sell | AVROBIO, Inc. | $2,494,000 | -48.1% | 647,918 | -24.8% | 0.46% | -39.0% |
| INZY | Sell | Inozyme Pharma Inc. | $2,064,000 | -44.5% | 302,615 | -5.6% | 0.38% | -34.8% |
| BDTX | Sell | Black Diamond Therapeutics, Inc. | $1,279,000 | -39.2% | 239,888 | -3.5% | 0.23% | -28.5% |
| LHDX | Exit | Lucira Health Inc. | $0 | – | -578,114 | -100.0% | -0.68% | – |
| Exit | MEI Pharma, Inc. | $0 | – | -12,494,118 | -100.0% | -5.35% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.